EE04589B1 - Vähivastaste ühendite valmistamise protsessid ja vaheühendid - Google Patents

Vähivastaste ühendite valmistamise protsessid ja vaheühendid

Info

Publication number
EE04589B1
EE04589B1 EEP200000255A EEP200000255A EE04589B1 EE 04589 B1 EE04589 B1 EE 04589B1 EE P200000255 A EEP200000255 A EE P200000255A EE P200000255 A EEP200000255 A EE P200000255A EE 04589 B1 EE04589 B1 EE 04589B1
Authority
EE
Estonia
Prior art keywords
intermediates
processes
preparation
anticancer compounds
anticancer
Prior art date
Application number
EEP200000255A
Other languages
English (en)
Estonian (et)
Inventor
Shelton Lehner Richard
Norris Timothy
Paul Santafianos Dinos
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of EE200000255A publication Critical patent/EE200000255A/xx
Publication of EE04589B1 publication Critical patent/EE04589B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
    • C22B15/00—Obtaining copper
    • C22B15/0002—Preliminary treatment
    • C22B15/0004—Preliminary treatment without modification of the copper constituent
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
    • C22B15/00—Obtaining copper
    • C22B15/0063—Hydrometallurgy
    • C22B15/0065—Leaching or slurrying
    • C22B15/0067—Leaching or slurrying with acids or salts thereof
    • C22B15/0071—Leaching or slurrying with acids or salts thereof containing sulfur
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P10/00—Technologies related to metal processing
    • Y02P10/20—Recycling
EEP200000255A 1999-03-31 2000-03-30 Vähivastaste ühendite valmistamise protsessid ja vaheühendid EE04589B1 (et)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12707299P 1999-03-31 1999-03-31

Publications (2)

Publication Number Publication Date
EE200000255A EE200000255A (et) 2000-12-15
EE04589B1 true EE04589B1 (et) 2006-02-15

Family

ID=22428179

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000255A EE04589B1 (et) 1999-03-31 2000-03-30 Vähivastaste ühendite valmistamise protsessid ja vaheühendid

Country Status (50)

Country Link
US (1) US6476040B1 (xx)
EP (1) EP1044969B1 (xx)
JP (2) JP3420549B2 (xx)
KR (2) KR100430210B1 (xx)
CN (2) CN100351242C (xx)
AP (2) AP1265A (xx)
AR (1) AR018705A1 (xx)
AT (1) ATE348098T1 (xx)
AU (2) AU781402B2 (xx)
BG (1) BG65194B1 (xx)
BR (1) BRPI0001486B8 (xx)
CA (2) CA2427221C (xx)
CO (1) CO5160273A1 (xx)
CR (1) CR6165A (xx)
CZ (1) CZ299426B6 (xx)
DE (1) DE60032275T2 (xx)
DK (1) DK1044969T3 (xx)
DZ (1) DZ3030A1 (xx)
EA (3) EA005892B1 (xx)
EE (1) EE04589B1 (xx)
EG (1) EG22506A (xx)
ES (1) ES2278578T3 (xx)
GE (1) GEP20022653B (xx)
GT (1) GT200000037A (xx)
HK (1) HK1029790A1 (xx)
HR (1) HRP20000182B1 (xx)
HU (1) HU227698B1 (xx)
ID (1) ID25427A (xx)
IL (2) IL168036A (xx)
IS (1) IS2468B (xx)
MA (1) MA25087A1 (xx)
MY (1) MY136270A (xx)
NO (2) NO321952B1 (xx)
NZ (2) NZ503683A (xx)
OA (1) OA11335A (xx)
PA (1) PA8491901A1 (xx)
PE (1) PE20001599A1 (xx)
PL (1) PL339330A1 (xx)
PT (1) PT1044969E (xx)
RS (1) RS49836B (xx)
SG (2) SG121687A1 (xx)
SK (1) SK287339B6 (xx)
SV (1) SV2002000047A (xx)
TN (1) TNSN00064A1 (xx)
TR (1) TR200000837A2 (xx)
TW (1) TW553939B (xx)
UA (2) UA70928C2 (xx)
UY (1) UY26086A1 (xx)
YU (1) YU13200A (xx)
ZA (1) ZA200001586B (xx)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
EP1415987B1 (en) 2000-10-20 2007-02-28 Eisai R&D Management Co., Ltd. Nitrogenous aromatic ring compounds as anti cancer agents
WO2003000188A2 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel quinazolines and uses thereof
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
EP2277867B1 (en) 2002-07-15 2012-12-05 Symphony Evolution, Inc. Compounds, pharmaceutical compositions thereof and their use in treating cancer
US7148231B2 (en) 2003-02-17 2006-12-12 Hoffmann-La Roche Inc. [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
JPWO2004080462A1 (ja) 2003-03-10 2006-06-08 エーザイ株式会社 ｃ−Ｋｉｔキナーゼ阻害剤
WO2005003100A2 (en) 2003-07-03 2005-01-13 Myriad Genetics, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
US8309562B2 (en) * 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
WO2006074147A2 (en) 2005-01-03 2006-07-13 Myriad Genetics, Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
WO2005026150A1 (en) 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
DK2392564T3 (da) 2003-09-26 2014-01-13 Exelixis Inc c-Met-modulatorer og anvendelsesfremgangsmåder
CN101337930B (zh) 2003-11-11 2010-09-08 卫材R&D管理有限公司 脲衍生物的制备方法
GEP20084551B (en) * 2004-05-06 2008-11-25 Warner Lambert Co 4-phenylamino-quinazolin-6-yl-amides
EP1797881B1 (en) 2004-09-17 2009-04-15 Eisai R&D Management Co., Ltd. Medicinal composition with improved stability and reduced gelation properties
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
US7625911B2 (en) * 2005-01-12 2009-12-01 Mai De Ltd. Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion
CN101163468A (zh) * 2005-02-28 2008-04-16 卫材R&D管理有限公司 磺酰胺化合物的新联合用途
JP5066446B2 (ja) * 2005-08-01 2012-11-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を予測する方法
EP2281901B1 (en) 2005-08-02 2013-11-27 Eisai R&D Management Co., Ltd. Anti-tumour pharmaceutical composition with angiogenesis inhibitors
US20090053236A1 (en) * 2005-11-07 2009-02-26 Eisai R & D Management Co., Ltd. USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR
WO2007061130A1 (ja) * 2005-11-22 2007-05-31 Eisai R & D Management Co., Ltd. 多発性骨髄腫に対する抗腫瘍剤
EP2036557B1 (en) * 2006-05-18 2015-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for thyroid cancer
JPWO2008001956A1 (ja) * 2006-06-29 2009-12-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 肝線維症治療剤
CN101547910A (zh) 2006-07-28 2009-09-30 合成纤维有限公司 结晶埃罗替尼
KR101472600B1 (ko) 2006-08-28 2014-12-15 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암에 대한 항종양제
US8372856B2 (en) * 2006-10-27 2013-02-12 Synthon Bv Hydrates of erlotinib hydrochloride
EP2116246A1 (en) 2007-01-19 2009-11-11 Eisai R&D Management Co., Ltd. Composition for treatment of pancreatic cancer
JP5319306B2 (ja) 2007-01-29 2013-10-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 未分化型胃癌治療用組成物
PT2170844T (pt) * 2007-02-21 2016-08-05 Natco Pharma Ltd Novos polimorfos de cloridrato de erlotinib e método de preparação
KR101441930B1 (ko) 2007-04-04 2014-09-19 시플라 리미티드 에르로티닙 및 그의 약학적으로 허용가능한 염의 제조방법
US20090012295A1 (en) * 2007-06-25 2009-01-08 Ales Gavenda Amorphous Erlotinib, processes for the preparation thereof, and processes to prepare additional forms of Erlotinib
US8389531B2 (en) 2007-07-11 2013-03-05 Hetero Drugs Limited Process for erlotinib hydrochloride
US20090131665A1 (en) * 2007-08-23 2009-05-21 Ales Gavenda Process for the preparation of crystalline forms A, B and pure crystalline form a of erlotinib HCI
US20090124642A1 (en) * 2007-08-23 2009-05-14 Augusto Canavesi Crystalline forms of Erlotinib HCI and formulations thereof
US20090076042A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched erlotinib
US8952035B2 (en) 2007-11-09 2015-02-10 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
MX2010008187A (es) * 2008-01-29 2010-08-10 Eisai R&D Man Co Ltd Uso combinado de inhibidor de angiogenesis y taxano.
CN102083801A (zh) * 2008-03-28 2011-06-01 康瑟特制药公司 喹唑啉衍生物和治疗方法
WO2010005924A1 (en) * 2008-07-07 2010-01-14 Plus Chemicals Sa Crystalline forms of erlotinib base and erlotinib hcl
KR101132937B1 (ko) 2008-10-01 2012-04-06 주식회사종근당 Ｎ-(3-에티닐페닐)-6,7-비스(2-메톡시에톡시)-4-퀴나졸린아민 납실레이트 염
WO2010040212A1 (en) * 2008-10-08 2010-04-15 Apotex Pharmachem Inc. Processes for the preparation of erlotinib hydrochloride
SG173014A1 (en) 2009-01-16 2011-08-29 Exelixis Inc Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl)-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer
US8440823B2 (en) 2009-03-26 2013-05-14 Ranbaxy Laboratories Limited Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
WO2011058525A2 (en) 2009-11-12 2011-05-19 Ranbaxy Laboratories Limited Processes for the preparation of erlotinib hydrochloride form a and erlotinib hydrochloride form b
WO2011068404A2 (en) 2009-12-02 2011-06-09 Ultimorphix Technologies B.V. Administration of n-(3-ethynylphenylamino)-6,7-bis(2- methoxyethoxy)-4-quinazolinamine mesylate salt by inhalation
CN102958523B (zh) 2010-06-25 2014-11-19 卫材R&D管理有限公司 使用具有激酶抑制作用的组合的抗肿瘤剂
US8952022B2 (en) 2010-07-23 2015-02-10 Generics [Uk] Limited Pure erlotinib
IT1402029B1 (it) 2010-10-14 2013-08-28 Italiana Sint Spa Procedimento per la preparazione di erlotinib
WO2012144463A1 (ja) 2011-04-18 2012-10-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CN102267952B (zh) * 2011-06-21 2013-12-11 天津市汉康医药生物技术有限公司 喹唑啉类化合物、其制备方法和用途
CN103420924B (zh) * 2012-05-25 2016-08-31 浙江九洲药业股份有限公司 一种盐酸埃罗替尼晶型a的制备方法
WO2014037961A1 (en) 2012-09-04 2014-03-13 Shilpa Medicare Limited Crystalline erlotinib hydrochloride process
BR112015009004A8 (pt) 2012-12-21 2021-07-20 Eisai R&D Man Co Ltd forma amorfa de derivado de quinolina e método de produção da mesma
WO2014118737A1 (en) 2013-01-31 2014-08-07 Ranbaxy Laboratories Limited Erlotinib salts
MX368099B (es) 2013-05-14 2019-09-19 Eisai R&D Man Co Ltd Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib.
CN103333124B (zh) * 2013-05-28 2015-03-25 埃斯特维华义制药有限公司 一种制备盐酸厄洛替尼晶型f的方法
HRP20221047T1 (hr) 2014-08-28 2022-11-11 Eisai R&D Management Co., Ltd. Derivat kinolina visoke čistoće i postupak za njegovu proizvodnju
CA2908441A1 (en) 2014-10-28 2016-04-28 Cerbios-Pharma Sa Process for the preparation of erlotinib
CN107427505A (zh) 2015-02-25 2017-12-01 卫材R&D管理有限公司 用于抑制喹啉衍生物的苦味的方法
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
US11369623B2 (en) 2015-06-16 2022-06-28 Prism Pharma Co., Ltd. Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor
CN105884653A (zh) * 2016-06-08 2016-08-24 浙江汇能生物股份有限公司 一种埃罗替尼衍生物及其制备方法
CN106279585A (zh) * 2016-08-26 2017-01-04 宁波圣达精工智能科技有限公司 一种阻燃智能密集书架的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4747498A (en) * 1986-06-27 1988-05-31 Sunbeam Plastics Corporation Safety dispensing closure-container package
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
JP2657760B2 (ja) * 1992-07-15 1997-09-24 小野薬品工業株式会社 ４−アミノキナゾリン誘導体およびそれを含有する医薬品
EP0817775B1 (en) * 1995-03-30 2001-09-12 Pfizer Inc. Quinazoline derivatives
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
IL125686A (en) 1996-02-13 2002-11-10 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical preparations containing them and their use in the manufacture of a drug with an anti-angiogenic effect and / or an effect of reducing vascular permeability
DE69709319T2 (de) 1996-03-05 2002-08-14 Astrazeneca Ab 4-anilinochinazolin derivate
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6225499B1 (en) 1997-07-14 2001-05-01 Catalytica Pharmaceuticals, Inc. Process for preparing aminoarylacetylenes
TR200003166T2 (tr) 1998-04-29 2001-02-21 Osi Pharmaceuticals, Inc. N-(3-etinilfenilamino)-6, 7-bis(2-metoksietoksi)-4-kuinozolamin mesilat anhidrat ve monohidrat.

Also Published As

Publication number Publication date
JP3420549B2 (ja) 2003-06-23
NO20054715L (no) 2000-10-02
CA2302965A1 (en) 2000-09-30
IS2468B (is) 2008-12-15
PE20001599A1 (es) 2001-01-18
SG121687A1 (en) 2006-05-26
CZ20001155A3 (cs) 2001-03-14
BRPI0001486B8 (pt) 2021-05-25
GT200000037A (es) 2001-09-21
HUP0001353A2 (hu) 2001-05-28
NO20001648D0 (no) 2000-03-30
KR100430209B1 (ko) 2004-05-03
CO5160273A1 (es) 2002-05-30
US6476040B1 (en) 2002-11-05
AP1265A (en) 2004-03-26
AP1655A (en) 2006-09-01
DE60032275T2 (de) 2007-07-12
CN1276370A (zh) 2000-12-13
TW553939B (en) 2003-09-21
CR6165A (es) 2008-10-10
CZ299426B6 (cs) 2008-07-23
UA70928C2 (uk) 2004-11-15
CA2302965C (en) 2004-02-17
EA200201245A1 (ru) 2003-04-24
JP4074509B2 (ja) 2008-04-09
HU227698B1 (en) 2011-12-28
PT1044969E (pt) 2007-05-31
EA200000274A3 (ru) 2003-02-27
ES2278578T3 (es) 2007-08-16
NO324745B1 (no) 2007-12-03
TNSN00064A1 (fr) 2005-11-10
KR20010014658A (ko) 2001-02-26
TR200000837A2 (tr) 2000-11-21
EP1044969B1 (en) 2006-12-13
IL135245A0 (en) 2001-05-20
JP2000290262A (ja) 2000-10-17
EE200000255A (et) 2000-12-15
DZ3030A1 (fr) 2004-03-27
AU2005201494A1 (en) 2005-05-05
SG115536A1 (en) 2005-10-28
GEP20022653B (en) 2002-03-25
BG104278A (en) 2001-08-31
NO321952B1 (no) 2006-07-24
HRP20000182A2 (en) 2001-04-30
EP1044969A3 (en) 2000-11-29
EA200201244A1 (ru) 2003-04-24
KR100430210B1 (ko) 2004-05-03
AR018705A1 (es) 2001-11-28
UY26086A1 (es) 2000-10-31
DE60032275D1 (de) 2007-01-25
EG22506A (en) 2003-03-31
EP1044969A2 (en) 2000-10-18
CA2427221A1 (en) 2000-09-30
ZA200001586B (en) 2001-10-01
JP2003176274A (ja) 2003-06-24
HK1029790A1 (en) 2001-04-12
SK287339B6 (sk) 2010-07-07
NZ503683A (en) 2001-09-28
NZ512818A (en) 2003-01-31
KR20020084903A (ko) 2002-11-13
ID25427A (id) 2000-10-05
EA005892B1 (ru) 2005-06-30
BRPI0001486B1 (pt) 2019-01-29
DK1044969T3 (da) 2007-04-23
EA200000274A2 (ru) 2000-10-30
RS49836B (sr) 2008-08-07
AP2000001778A0 (en) 2000-03-31
AU2262000A (en) 2000-10-05
YU13200A (sh) 2002-10-18
UA80955C2 (en) 2007-11-26
OA11335A (en) 2003-12-10
CN1215061C (zh) 2005-08-17
CN100351242C (zh) 2007-11-28
SK4442000A3 (en) 2000-10-09
PA8491901A1 (es) 2001-12-14
NO20001648L (no) 2000-10-02
MY136270A (en) 2008-09-30
ATE348098T1 (de) 2007-01-15
CN1699350A (zh) 2005-11-23
AU781402B2 (en) 2005-05-19
HU0001353D0 (en) 2000-06-28
BR0001486A (pt) 2001-05-02
SV2002000047A (es) 2002-01-23
EA004654B1 (ru) 2004-06-24
BG65194B1 (bg) 2007-06-29
EA005561B1 (ru) 2005-04-28
PL339330A1 (en) 2000-10-09
HUP0001353A3 (en) 2002-01-28
AU2005201494B2 (en) 2008-02-07
IS5411A (is) 2000-10-02
HRP20000182B1 (en) 2007-10-31
IL168036A (en) 2006-12-10
MA25087A1 (fr) 2000-10-01
CA2427221C (en) 2008-09-16

Similar Documents

Publication Publication Date Title
EE04589B1 (et) Vähivastaste ühendite valmistamise protsessid ja vaheühendid
FI20000564A (fi) Menetelmä nanolaminaattien valmistamiseksi
FI20010154A (fi) Menetelmä citalopramin valmistamiseksi
NO20015017D0 (no) Fremgangsmåte for fremstilling av citalopram
NO20010319D0 (no) Fremgangsmåte for fremstilling av Citalopram
PT1210113E (pt) Composicoes de vacinas de combinacao
NO20042680L (no) Fremgangsmater for fremstilling av O-demetylvenflaxine
EE200100259A (et) Moksifloksatsiini farmatseutiline preparaat
EE04747B1 (et) Amiini-plaatina komplekside valmistamismeetod
FI20011622A (fi) Menetelmä sitalopraamin valmistamiseksi
NO20016151D0 (no) Fremstilling av substituerte piperidin-4-oner
NO20003454L (no) FremgangsmÕte for fremstilling av (-)cis-3-hydroksy-1-metyl-4-
NO996432L (no) Fremgangsmåte for fremstilling av 4-substituert-1H-indol-3- glykosamider
PT1175417E (pt) Compostos substituidos de benzolactamas
ITMI992048A0 (it) Procedimento stereoselettivo per la preparazione di endo-3-amminoazabi cicloalcani
DK1177165T3 (da) Fremgangsmåde til fremstilling af pesticidmellemprodukter
NO20022956D0 (no) Fremgangsmåte for fremstilling av nitroguanidin
NO20000805L (no) FremgangsmÕte for fremstilling av organiske azider
EE200100333A (et) Meetod 2-halo-3-nitro-4-aminopüridiini valmistamiseks ja selleks vajalike vaheühendite saamine
NO20020328D0 (no) Fremgangsmåte for fremstilling av 4-cyano-2-aminometyltiazol
NO20020327D0 (no) Fremgangsmåte for fremstilling av 2-aminometyl-4-cyano-tiazol
NO20003077D0 (no) FremgangsmÕte for fremstilling av klorbenzooksazolen
NO994557D0 (no) Fremgangsmaate for fremstilling av arylaminotriazolopyridiner
NO982975D0 (no) FremgangsmÕte for fremstilling av fosfatbundne keramer
NO20002558D0 (no) FremgangsmÕte for fremstilling av findisperse eksplosivstoffer

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner
KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20110330